CanAssist Breast Provides Additional Insightful Prognostic Information in Retrospective, Pooled Secondary Analysis in Clinically Low/ High-Risk Patients With HR+/HER2- EBC
Clinical Breast Cancer · 2026
DOI: 10.1016/j.clbc.2025.08.022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Tejal Deepak Durgekar und 7 weiteren Autor:innen. Beteiligte Einrichtung: OncoStem Diagnostics Private Limited, Bangalore, Karnataka 560027, India. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: In patients with early-stage HR+/ HER2- breast cancer, younger age, node positivity (N+), and higher Ki67 index are considered ``clinically high-risk'' and are treated with chemotherapy, although some can do well without it. Chemotherapy is often avoided in ``clinically low-risk'' patients with older age, small (T1-T2) or node-negative (N0) or lower Ki67 tumors; however, some of these patients do recur. Unlike earlier studies, this study aimed to explore the potential of CanAssist Breast (CAB), a prognostic test in providing ``additional'' information beyond ``clinicopathological parameters'' in ``clinically'' low-risk/ high-risk patients for effective treatment management. METHODS: This is a secondary pooled data analysis of previously published retrospective studies wherein CAB risk stratification data of 3045 patients were used to assess the risk of recurrence at five years from diagnosis. Distant recurrence-free interval (DRFI) was evaluated from Kaplan-Meier curves. RESULTS: In patients having N0 disease, CAB identified 13% and 8% high-risk patients with small tumors and small tumors with low Ki67 levels, respectively. In patients with N+ disease, CAB identified 44% of patients with higher Ki67 (≥20%) as low-risk. In younger patients, CAB identified >46% of patients as low-risk. In low ER-expressing patients, CAB identified 67% of patients as low-risk. All CAB low-risk patients have an acceptable DRFI of ≥ 89% at five years from diagnosis. CONCLUSIONS: CAB provides additional prognostic information by identifying ``low-risk'' and ``high-risk'' patients from the ``clinically'' high-risk and low-risk groups, thereby guiding oncologists to either avoid aggressive therapies or govern significant treatment decisions on additional therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- OncoStem Diagnostics Private Limited, Bangalore, Karnataka 560027, India.
- OncoStem Diagnostics Private Limited, Bangalore, Karnataka 560027, India. Electronic address: manjiri@oncostemdiagnostics.com.
Zitieren
APA
Durgekar, T. D., Ghosh, S., Savitha, B. A., Shrivastava, P., Krishnamoorthy, N., Sunder, M., Ks, D., & Bakre, M. (2026). CanAssist Breast Provides Additional Insightful Prognostic Information in Retrospective, Pooled Secondary Analysis in Clinically Low/ High-Risk Patients With HR+/HER2- EBC. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.08.022
Vancouver
Durgekar TD, Ghosh S, Savitha BA, Shrivastava P, Krishnamoorthy N, Sunder M, et al. CanAssist Breast Provides Additional Insightful Prognostic Information in Retrospective, Pooled Secondary Analysis in Clinically Low/ High-Risk Patients With HR+/HER2- EBC. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2025.08.022
BibTeX
@article{Durgekar2026,
author = {Durgekar, Tejal Deepak and Ghosh, Susmita and Savitha, Badada Ananthamurthy and Shrivastava, Payal and Krishnamoorthy, Naveen and Sunder, Manvi and Ks, Deepti and Bakre, Manjiri},
title = {CanAssist Breast Provides Additional Insightful Prognostic Information in Retrospective, Pooled Secondary Analysis in Clinically Low/ High-Risk Patients With HR+/HER2- EBC},
journal = {Clinical Breast Cancer},
year = {2026},
doi = {10.1016/j.clbc.2025.08.022}
}
EUVIMED